Skip to main content
EN
Caution:
At present, there are occasional discrepancies in the display of intellectual property rights holders and their representatives. We are working on a solution.
Patent Search
Details
Details for 2019711866
Up to date per 04.06.2026
Actions
Copy link to European Patent
Download Registration Print
Details
Details for 2019711866
Title / Product Name
NEUE PHARMAZEUTISCHE FORMULIERUNG MIT DUALEN NK-1/NK-3-REZEPTOR-ANTAGONISTEN.
Status
Granted/Registered
Protection Type
European Patent
(AT-) Application Number
2019711866
EP Publication Number
3765024
E-Number
1633758
Language
EN
PCT Number
EP19056303
Publication Date
20.01.2021 A
22.11.2023 B1
Registration Date
22.11.2023
AT Publication Date
15.12.2023
Application Date
13.03.2019
Registration Number
-
Priorities
14.03.2018
US
201862642622 P
IPC
C07D 498/04 20060101AFI20230501BHEP
Maximum Duration of Protection
13.03.2039
Owner
KaNDy Therapeutics Limited
400 South Oak Way
Reading, Berkshire RG2 6AD
GB
Representative
Representative
Häupl & Ellmeyer KG, Patentanwaltskanzlei
Mariahilfer Straße 50 (Kirchengasse 1)
1070 Wien
AT
Inventor
TROWER, Mike
C/O NeRRe Therapeutics Limited Stevenage Bioscience Catalyst Incubator Building Gunnels Wood Road
Stevenage Hertfordshire SG1 2FX
GB
KERR, Mary
C/O NeRRe Therapeutics Limited Stevenage Bioscience Catalyst Incubator Building Gunnels Wood Road
Stevenage Hertfordshire SG1 2FX
GB
ELDER, David
110 Fordwich Rise
Hertford, Hertfordshire SG14 2DE
GB
LAZARO, Monica
C/O Catalent Pharma Solutions 2725 Scherer Drive
St. Petersburg, Florida 33716
US
BUSH, Derek
C/O Catalent Pharma Solutions 2725 Scherer Drive
St. Petersburg, Florida 33716
US
Information about Fees
Click here to load the fees